NCT03179904 - TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 3, 2017

Primary Completion Date

July 30, 2024

Study Completion Date

December 31, 2025

Conditions

Advanced Breast CarcinomaHER2-Positive Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8HER2-positive Breast Cancer

Interventions

DRUG

Anastrozole

Given PO

DRUG

Denifanstat

Given PO

DRUG

Exemestane

Given PO

DRUG

Fulvestrant

Given IM

PROCEDURE

Echocardiography

Undergo ECHO

DRUG

Letrozole

Given PO

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Trastuzumab

Given IV

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Biopsy

Undergo biopsy

Trial Locations (3)

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville